FIELD: medicine.
SUBSTANCE: group of inventions relates to the treatment of haematological malignant diseases. Combination for treating a hyperproliferative disorder contains a compound of formula (I) or a pharmaceutically acceptable salt thereof, a BCL2 inhibitor selected from venetoclax, ABT-737 and pharmaceutically acceptable salts thereof. 
Also disclosed are a pharmaceutical composition, a kit, methods of treating a hyperproliferative disorder, using a combination for treating a hyperproliferative disorder and for preparing a drug.
EFFECT: group of inventions provides achieving a synergetic effect on cancer cell inhibition.
40 cl, 22 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF LSD1 INHIBITORS FOR TREATING HAEMATOLOGICAL MALIGNANT DISEASES | 2017 |
|
RU2766259C2 |
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
| COMBINATION OF MCL-1 INHIBITOR AND MIDOSTAURIN, ITS APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS | 2019 |
|
RU2818453C2 |
| COMBINATION OF CHEKPOINT-KINASE 1 INHIBITORS AND WEE 1 KINASE INHIBITORS | 2011 |
|
RU2627841C2 |
| COMBINATION OF BCL-2 INHIBITOR AND MCL-1 INHIBITOR, USE AND PHARMACEUTICAL COMPOSITIONS THEREOF | 2017 |
|
RU2746705C2 |
| RARA AGONISTS FOR THE TREATMENT OF AML AND MDS | 2017 |
|
RU2799789C2 |
| TREATING MALIGNANT TUMOURS USING MODULATORS OF PI3-KINASE ISOFORMS | 2013 |
|
RU2702908C2 |
| METHODS OF TREATING CANCER USING APILIMOD | 2016 |
|
RU2738934C2 |
| TREATING MALIGNANT TUMORS USING PIZ-KINASE ISOFORM MODULATORS | 2014 |
|
RU2705204C2 |
| COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | 2016 |
|
RU2759963C2 |
